Suzhou OSAI Biopharma

Suzhou OSAI Biopharma is a clinical-stage biopharmaceutical company headquartered in Suzhou Biobay, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages a structure-based drug design (SBDD) platform to target high-value pathways in oncology and immunology, with a particular focus on kinase inhibitors. Its lead programs include highly selective IRAK4 inhibitors for hematological malignancies and autoimmune disorders, as well as next-generation CDK inhibitors for solid tumors. OSAI Biopharma aims to address unmet medical needs by developing best-in-class or first-in-class oral medications with improved safety and efficacy profiles.